Cervical Cancer Diagnostic Test Market Size, Outlook, Trends Report 2032

Cervical Cancer Diagnostic Test Market Insights

According to Zion Market Research, the global Cervical Cancer Diagnostic Test Market was worth USD 8.25 Billion in 2023. The market is forecast to reach USD 13.05 Billion by 2032, growing at a compound annual growth rate (CAGR) of 5.22% during the forecast period 2024-2032.

The report offers a comprehensive analysis of the market, highlighting the factors that will determine growth, potential challenges, and opportunities that could emerge in the Cervical Cancer Diagnostic Test Market industry over the next decade.

Request Free Sample

Amongst the types of cancer identified as of now, cervical cancer is the one most prevalent amongst women. Research also states that 90% of the cases of cervical cancer could be attributed to HPV infection. The diagnosis happens through smear screening. The last few years have seen a substantial increase in the population of female smokers. Plus, the frequency of unsafe sex is increasing among teenagers. Therefore, the rate of cervical cancer is increasing in the young population.

Cancer is defined as abnormal growth of cells with the potential to spread to other parts of the body. There are various types of cancer affecting different parts of the body. Cancer which develops in the cervix is called as cervical cancer. Two major types of cervical cancers diagnosed in women include adenocarcinoma and squamous cell carcinoma. Almost all types of cervical cancer are caused by human papiloma virus (HPV). Cervical cancer is the third most common cancer among women and the second most frequent cause of cancer-related death, accounting for almost 3,00,000 deaths annually. Diagnosis of cervical cancer is done by pap smear tests, colposcopy, HPV testing, endocervical curettage (ECC). Cervical cancer is a sexually transmitted disease that can be prevented by early detection and vaccination.

Globally, cervical cancer diagnostic test market has been accelerated by increasing the percentage of HPV infected female population across the globe. According to the Center for Disease Control and Prevention (CDC), six million people in the U.S. acquire HPV each year.  At least 20 million already suffer from cervical cancer, and more than half of all sexually-active adults will be infected during their lifetime. Furthermore increasing the incidence of weakened immune system coupled with certain life history is also considered as a major governing factor which promotes the cause of cervical cancer in female and thus promotes the cervical cancer diagnostic market. Moreover many lifestyle-related factors, such as having multiple sex partners, smoking, obesity, unsafe sex and inherited HPV-positive patient, are estimated to drive the cervical diagnostics market. However, lack of education regarding the prevalence of cervical cancer and the unwillingness of the female population to undergo cervical cancer prognosis would hinder the growth of the market. In addition, HPV vaccination which makes people hesitant for conducting cervical cancer diagnostic test is also one of the restraining factors in a growth of cervical cancer diagnostic market.

Covid Impact Analysis

The outbreak of COVID-19 has escalated the cervical cancer diagnostic tests, more so as the WHO has certified that those suffering from chronic diseases like cancer, and diabetes are more likely to contract Corona. These patients are trying to be doubly sure about the complexities so that utmost care can be taken amidst the ongoing pandemic. The market for cervical cancer diagnostic tests is not expected to stand still by any means, looking at the situation on the whole.

Request Free Sample

Cervical Cancer Diagnostic Test Market: Dynamics

The global cervical cancer diagnostic test market is significantly driven by the rise in the percentage of HPV in the female population. Lack of hygiene and non-awareness of cervical cancer in women is one of the significant factors to boost the need for cervical cancer diagnostic tests in women.

According to the CDC, more than seven million people acquire HPV in the U.S. Besides, changes in lifestyle, and availability of medical support are expected to propel the market growth. Genetic causes in women are also anticipated to contribute to the market growth in the coming years.

Cervical Cancer Diagnostic Test Market: Report Scope

Cervical Cancer Diagnostic Test Market: Segmentation Analysis

Segmentation Analysis by Test 

Based on the test, the global market of cervical cancer diagnostic test market is segmented as Pap smear tests, colposcopy, HPV testing, endocervical curettage (ECC), and others.

Based on the test, the global market of cervical cancer diagnostic test is bifurcated into five types: Pap smear tests, colposcopy, HPV testing, endocervical curettage (ECC) and others (Cone Biopsy and Loop Electrosurgical Excision Procedure). The Pap smear tests segment accounted for the largest share of approximately more than 50% of the total cervical cancer diagnostic tests market in 2015. Factors attributed to the dominance of Pap smear tests are lower test prices and growing awareness about cancer diagnosis and benefits of early detection. Similarly, the HPV testing is forecast to grow at the fastest growth rate of approximately more than 9% from 2015 to 2021 of the cervical cancer diagnostic tests market. The rapid growth of the HPV testing segment is attributed due to the increasing incidence of HPV infections and risk of abnormal Pap test.

Segmentation Analysis by End-User

Based on end-users, the global market of cervical cancer diagnostics test market is trifurcated into hospitals, laboratories, and others. The hospitals segment was the leading segment in 2023. The segment is expected to continue its dominance during the forecast period.

Based on geographies, the global market of cervical cancer diagnostics/test is bifurcated into five regions: North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. These segments are further bifurcated into the U.S., UK, Germany, France, China, Japan, India, and Brazil. North America accounted for the largest share of the global cervical cancer diagnostics/test market, followed by Europe. This growth is attributed due to rising awareness related to health care in this region. Moreover, cervical cancer diagnostics/test market has the huge opportunity in the emerging markets of Asia Pacific due to increasing standard of living, large patient base in this region. The Asia-Pacific market is projected to grow at the highest CAGR during the forecast period, due to the rising incidence of cervical cancer, increasing government support, and growing upper middle-class population and rise in disposable income levels in this region.

Cervical Cancer Diagnostic Test Market: Regional Analysis

North America held a significant share owing rise in awareness and presence of key players. Moreover, developed medical infrastructure offers lucrative opportunities for market development shortly. The Asia Pacific is the second leading market for cervical cancer diagnostic tests owing to the large population with unmet medical needs. The rise in the geriatric population is one of the major reasons for growth within regional markets.

Request Free Sample

Cervical Cancer Diagnostic Test Market: Competitive Analysis

Some of the key players in the cervical cancer diagnostic test market include;

• Abbott Laboratories
• Becton
• Dickinson and Company
• Femasys Inc.
• Hologic Inc.
• Oncohealth Corp
• Quest Diagnostics Inc
• QIAGEN and Zilico Ltd.

The Global Cervical Cancer Diagnostic Test Market is segmented into:

By Test:

• Pap Smear Tests
• Colposcopy
• HPV Testing
• Endocervical Curettage (ECC)
• Others

By End-User:

• Hospitals
• Laboratories
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa